1 |
Churilov I, Churilov L, Brock K, et al. Sarcopenia is associated with reduced function on admission to rehabilitation in patients with diabetes[J]. J Clin Endocrinol Metab, 2021, 106 (2): e687-e695.
|
2 |
Zhou M, Wang H, Zhu J, et al. Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013[J]. Lancet, 2016, 387 (10015): 251-272.
|
3 |
Liguori I, Russo G, Aran L, et al. Sarcopenia: assessment of disease burden and strategies to improve outcomes[J]. Clin Interv Aging, 2018 (13): 913-927.
|
4 |
Chen LK, Woo J, Assantachai P, et al. Asian working group for sarcopenia: 2019 consensus update on sarcopenia diagnosis and treatment[J]. J Am Med Dir Assoc, 2020, 21 (3): 300-307.e2.
|
5 |
Zhao Y, Crimmins EM, Hu P, et al. Prevalence, diagnosis, and management of diabetes mellitus among older Chinese: results from the China Health and Retirement Longitudinal Study[J]. Int J Public Health, 2016, 61 (3): 347-356.
|
6 |
Javeed N, Matveyenko AV. Circadian etiology of type 2 diabetes mellitus[J]. Physiology (Bethesda), 2018, 33 (2): 138-150.
|
7 |
Cruz-Jentoft AJ, Sayer AA. Sarcopenia[J]. Lancet, 2019, 393 (10191): 2636-2646.
|
8 |
Kim TN, Park MS, Yang SJ, et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes: the Korean Sarcopenic Obesity Study (KSOS)[J]. Diabetes Care, 2010, 33 (7): 1497-1499.
|
9 |
Leenders M, Verdijk LB, van der Hoeven L, et al. Patients with type 2 diabetes show a greater decline in muscle mass,muscle strength, and functional capacity with aging[J]. J Am Med Dir Assoc, 2013, 14 (8): 585-592.
|
10 |
Anbalagan VP, Venkataraman V, Pradeepa R, et al. The prevalence of presarcopenia in Asian Indian individuals with and without type 2 diabetes[J]. Diabetes Technol Ther, 2013, 15 (9): 768-775.
|
11 |
Punkt K, Psinia I, Welt K, et al. Effects on skeletal muscle fibres of diabetes and Ginkgo biloba extract treatment[J]. Acta Histochem, 1999,101 (1): 53-69.
|
12 |
Morley JE, Malmstrom TK, Rodriguez-Manas L, et al. Frailty, sarcopenia and diabetes[J]. J Am Med Dir Assoc, 2014, 15 (12): 853-859.
|
13 |
Sinclair AJ, Abdelhafiz AH, Rodriguez-Manas L. Frailty and sarcopenia-newly emerging and high impact complications of diabetes[J]. J Diabetes Complications 2017, 31 (9): 1465-1473.
|
14 |
Ogama N, Sakurai T, Kawashima S, et al. Association of glucose fluctuations with sarcopenia in older adults with type 2 diabetes mellitus[J]. J Clin Med, 2019, 8 (3): 319.
|
15 |
Cleasby ME, Jamieson PM, Atherton PJ. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities[J]. J Endocrinol, 2016, 229 (2): R67-R81.
|
16 |
Sugimoto K, Tabara Y, Ikegami H, et al. Hyperglycemia in non-obese patients with type 2 diabetes is associated with low muscle mass: the Multicenter Study for Clarifying Evidence for Sarcopenia in Patients with Diabetes Mellitus[J]. J Diabetes Investig, 2019, 10 (6): 1471-1479.
|
17 |
Yanagita I, Fujihara Y, Eda T, et al. Low glycated hemoglobin level is associated with severity of frailty in Japanese elderly diabetes patients[J]. J Diabetes Investig, 2018, 9 (2): 419-425.
|
18 |
Vischer UM, Safar ME, Safar H, et al. Cardiometabolic determinants of mortality in a geriatric population:is there a "reverse metabolic syndrome"?[J]. Diabetes Metab, 2009, 35 (2): 108-114.
|